Found 0 matching trials
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma PHASE2 The hepatocellular carcinoma (HCC) represents more than 5% of all human mal...
Show More Location
D. Cotugno Hospital
Learn More & Join Trial
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study PHASE3 Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common her...
Show More Location
University "Federico II" of Naples
Learn More & Join Trial
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly PHASE1 The objectives of the protocol is to determine the maximum tolerated dose a...
Show More Location
Antwerp University Hospital
Learn More & Join Trial
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas PHASE2 To determine if combination of everolimus and octreotide exert an anti-tumo...
Show More Location
Assistance Publique Hôpitaux Marseille
Learn More & Join Trial
Circulating Tumor Cells and Tumor DNA in HCC and NET N/A Background Treatment and control of cancer is associated with high costs, t...
Show More Location
Department of Hepatology and Gastroenterology
Learn More & Join Trial
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients PHASE3 Currently, the first line treatment for acromegaly is surgery, in order to ...
Show More Location
Multiple Locations
Learn More & Join Trial
Octreotide LAR as Maintenance Treatment for Patients With NEC PHASE2 This is phase II study on the efficacy of octreotide lar as maintenance tre...
Show More Location
Beijing Cancer Hospital
Learn More & Join Trial
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias PHASE3 The purpose of this study is to determine whether 40 mg octreotide long-act...
Show More Learn More & Join Trial
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs PHASE2 Abnormal PI3K-Akt-mTOR (mammalian target of rapamycin) pathway signaling an...
Show More Location
Fondazione IRCCS Istituto Tumori Milano
Learn More & Join Trial
Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency PHASE3 The general aim of the trial is to assess the efficacy of one year treatmen...
Show More Location
Ospedale San giovanni di Dio
Learn More & Join Trial